secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001104659-24-087545
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat
--------------------------------------------------------------------------------

- Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.
- Cash $6.4M at June 30, 2024, down from $7.5M at Dec 31, 2023; raised $0.3M via ATM in Q2.
- R&D expenses $1.8M (Q2 2024) vs $1.7M (Q2 2023); G&A $2.3M vs $1.7M.
- Completed End-of-Phase 2 FDA meeting; agreement on Phase 3 and NDA plan for ibezapolstat (IBZ) for C. difficile.
- USPTO granted IBZ patent expiring June 2042 covering reduced recurrence and microbiome health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/0001104659-24-087545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/tm2421278d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer